Randomized single-blind trial reports pain score outcomes in blood-stasis osteoporotic pain, highlighting potential benefits of integrative therapy.
Key Points
To evaluate the clinical efficacy and safety of the empirical herbal formula Rumo zhentong Yin combined with standard therapy for treating blood-stasis-type osteoporotic pain.
Single-blind, randomized controlled trial allocating eligible osteoporotic pain patients 1:1 to standard therapy alone or standard therapy combined with Rumo zhentong Yin.
Intervention duration is 3 months with follow-up evaluations performed every 4 weeks.
The primary outcome is pain score, while secondary outcomes include bone mineral density, bone-turnover markers, inflammatory cytokines, blood-stasis syndrome score, and hematological indices.
As a study protocol, quantitative clinical outcome data and effect sizes are not yet reported.
The trial is designed to provide evidence on whether integrating this traditional Chinese medicine formula with standard Western care improves pain relief and bone metabolic markers.